A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: Evidence for a response-related difference in mitochondrial networks

British Journal of Pharmacology

Volumn 171, Issue 8, 2014, Pages 2230-2242

  Villasenor A ^a   Ramamoorthy, A ^b   Silva Dos Santos, M ^a,c   Lorenzo, M P ^a   Laje, G ^d,e,f   Zarate Jr , C ^d   Barbas, C ^a   Wainer, I W ^b  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e Department of Health and Human Services   (United States)

^f Maryland Institute for Neuroscience and Development (MIND)   (United States)

Author keywords

fatty acid metabolism; lithium; mitochondrial function; pharmacometabolomics; valproate

Indexed keywords

CARNITINE; KETAMINE; LITHIUM; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLETHANOLAMINE; MONOACYLGLYCEROL; N6,N6,N6 TRIMETHYL LEVO LYSINE; PHOSPHATIDYLETHANOLAMINE; PLACEBO; UNCLASSIFIED DRUG; VALPROIC ACID; ANTIDEPRESSANT AGENT; LYSOPHOSPHOLIPID; PHARMACOLOGICAL BIOMARKER;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; EVENING DOSAGE; FATTY ACID OXIDATION; FEMALE; HUMAN; MALE; METABOLOMICS; MITOCHONDRION; MORNING DOSAGE; PILOT STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; BIPOLAR DISORDER; BLOOD; CROSSOVER PROCEDURE; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG COMBINATION; DRUG EFFECTS; METABOLOME; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; BIOMARKERS, PHARMACOLOGICAL; BIPOLAR DISORDER; CROSS-OVER STUDIES; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KETAMINE; LITHIUM; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MALE; METABOLOME; MIDDLE AGED; PILOT PROJECTS; VALPROIC ACID; YOUNG ADULT;

EID: 84897409537     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12494     Document Type: Article

References (35)

1. Abo R, Hebbring S, Ji Y, Zhu H, Zeng Z-B, Batzler A, et al. (2012). Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics 22: 247-253.
2. Burroughs S, French D, (2007). Depression and anxiety: role of mitochondria. Curr Anaesth Crit Care 18: 34-41.
3. Ciborowski M, Teul J, Martin-Ventura JL, Egido J, Barbas C, (2012). Metabolomics with LC-QTOF-MS permits the prediction of disease stage in aortic abdominal aneurysm based on plasma metabolic fingerprint. PLoS ONE 7: e31982.
4. Di Cesare Mannelli L, Vivoli E, Salvicchi A, Schiovone N, Koverechi A, Messano M, et al. (2011). Antidepressant-like effect of artemin in mice: a mechanism for acetyl-L-carnitine activity on depression. Psychopharmacology (Berl) 218: 347-356.
5. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. (2010). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67: 793-802.
6. Dolgin E, (2013). Rapid antidepressant effects of ketamine ignite drug discovery. Nat Med 19: 8.
7. Horrobin DF, Bennett CN, (1999). Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 60: 217-234.
8. Hroudova J, Fisar Z, (2012). In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol Lett 213: 345-352.
9. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, et al. (2011). Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/ escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 89: 97-104.
10. Kaddurah-Daouk R, Krishnan K, (2009). Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34: 173-186.
11. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM, (2008). Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48: 653-683.
12. Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng ZB, et al. (2012). Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. Sci Rep 2: 667.
13. Lan MJ, McLoughlin GA, Griffin JL, Tsang TM, Huang JTJ, Yuan P, et al. (2009). Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psychiatry 14: 269-279.
14. Lheureux PE, Hantson P, (2009). Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 47: 101-111.
15. Lin L, Yu Q, Yan X, Hang W, Zheng J, Xing J, et al. (2010). Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer. Analyst 135: 2970-2978.
16. Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr, (2008). Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 69: 946-958.
17. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer HY, (1996). Fatty acid composition in major depression: decreased ω3 fractions in cholesteryl esters and increased c20:4ω6/c20:5ω3 ratio in cholesteryl esters and phospholipids. J Affect Disord 38: 35-46.
18. Milne S, Ivanova P, Forrester J, Alex Brown H, (2006). Lipidomics: an analysis of cellular lipids by ESI-MS. Methods 39: 92-103.
19. Minuzzi L, Behr GA, Moreira JCF, Frey BN, (2011). Mitochondrial dysfunction in bipolar disorder: lessons from brain imaging and molecular markers. Rev Colomb Psiquiatr 40: 166S-182S.
20. Modica-Napolitano JS, Renshaw PF, (2004). Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder. Biol Psychiatry 55: 273-277.
21. Nordin C, (1988). Relationships between clinical symptoms and monoamine metabolite concentrations in biochemically defined subgroups of depressed patients. Acta Psychiatr Scand 78: 720-729.
22. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC, (2007). A preliminary metabolomics analysis of older adults with and without depression. Int J Geriatr Psychiatry 22: 418-423.
23. Pettegrew JW, Levine J, McClure RJ, (2000). Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 5: 616-632.
24. Pettegrew JW, Levine J, Gershon S, Stanley JA, Servan-Schreiber D, Panchalingam K, et al. (2002). 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 4: 61-66.
25. Quinones MP, Kaddurah-Daouk R, (2009). Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 35: 165-176.
26. Rubingh CM, Bijlsma S, Derks EPPA, Bobeldijk I, Verheij ER, Kachar S, et al. (2006). Assessing the performance of statistical validation tools for megavariate metabolomics data. Metabolomics 2: 53-61.
27. Schwarz E, Bahn S, (2008). The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br J Pharmacol 153: S133-S136.
28. Silva MFB, Aires CCP, Luis PB, Ruiter JPN, Ijlst L, Duran M, et al. (2008). Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31: 205-216.
29. Steffens DC, Jiang W, Krishnan KRR, Karoly ED, Mitchell MW, O'Connor CM, et al. (2010). Metabolomic differences in heart failure patients with and without major depression. J Geriatr Psychiatry Neurol 23: 138-146.
30. Su YA, Wu J, Zhang L, Zhang Q, Su DM, He P, et al. (2008). Dysregulated mitochondrial genes and networks with drug targets in postmortem brain of patients with posttraumatic stress disorder (PTSD) revealed by human mitochondria-focused cDNA microarrays. Int J Biol Sci 4: 223-235.
31. Tang V, Wang JF, (2012). Oxidative stress in bipolar disorder. Biochem Anal Biochem S2-002. doi: 10.4172/2161-1009.S2-002.
32. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche ME, Ameli R, Luckenbaugh DA, et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
33. Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SLV, Ramamoorthy A, et al. (2012). Relationship of ketamine's plasma metabolites with efficacy, diagnosis, and psychotomimetic effects in patients with treatment-resistant depression. Biol Psychiatry 72: 331-338.
34. Zhang L, Zhou R, Li X, Ursano RJ, Li H, (2006). Stress-induced change of mitochondria membrane potential regulated by genomic and non-genomic GR signaling: a possible mechanism for hippocampus atrophy in PTSD. Med Hypotheses 66: 1205-1208.
35. Zhao X, Swarajya LV, Moaddel R, Luckenbaugh DA, Brutsche NE, Ibrahim L, et al. (2012). Simultaneous population pharmacokinetic modeling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol 74: 304-314.